AU2004309395C1 - Analogs of benzoquinone-containing ansamycins for the treatment of cancer - Google Patents

Analogs of benzoquinone-containing ansamycins for the treatment of cancer Download PDF

Info

Publication number
AU2004309395C1
AU2004309395C1 AU2004309395A AU2004309395A AU2004309395C1 AU 2004309395 C1 AU2004309395 C1 AU 2004309395C1 AU 2004309395 A AU2004309395 A AU 2004309395A AU 2004309395 A AU2004309395 A AU 2004309395A AU 2004309395 C1 AU2004309395 C1 AU 2004309395C1
Authority
AU
Australia
Prior art keywords
hydrogen
compound
alkyl
aralkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004309395A
Other languages
English (en)
Other versions
AU2004309395A1 (en
AU2004309395B2 (en
Inventor
Julian Adams
Yun Gao
Asimina T Georges Evangelinos
Louis Grenier
Roger H Pak
James R Porter
James L Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Infinity Discovery Inc
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34744040&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004309395(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of AU2004309395A1 publication Critical patent/AU2004309395A1/en
Assigned to INFINITY DISCOVERY, INC. reassignment INFINITY DISCOVERY, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: INFINITY PHARMACEUTICALS, INC
Application granted granted Critical
Publication of AU2004309395B2 publication Critical patent/AU2004309395B2/en
Publication of AU2004309395C1 publication Critical patent/AU2004309395C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2004309395A 2003-12-23 2004-12-23 Analogs of benzoquinone-containing ansamycins for the treatment of cancer Ceased AU2004309395C1 (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US53208003P 2003-12-23 2003-12-23
US60/532,080 2003-12-23
US54014204P 2004-01-29 2004-01-29
US60/540,142 2004-01-29
US54738104P 2004-02-23 2004-02-23
US60/547,381 2004-02-23
US56171804P 2004-04-12 2004-04-12
US60/561,718 2004-04-12
US56756504P 2004-05-03 2004-05-03
US60/567,565 2004-05-03
US60628304P 2004-09-01 2004-09-01
US60/606,283 2004-09-01
US62628604P 2004-11-09 2004-11-09
US60/626,286 2004-11-09
US63285804P 2004-12-03 2004-12-03
US60/632,858 2004-12-03
PCT/US2004/043162 WO2005063714A1 (en) 2003-12-23 2004-12-23 Analogs of benzoquinone-containing ansamycins for the treatment of cancer

Publications (3)

Publication Number Publication Date
AU2004309395A1 AU2004309395A1 (en) 2005-07-14
AU2004309395B2 AU2004309395B2 (en) 2011-10-06
AU2004309395C1 true AU2004309395C1 (en) 2012-10-04

Family

ID=34744040

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004309395A Ceased AU2004309395C1 (en) 2003-12-23 2004-12-23 Analogs of benzoquinone-containing ansamycins for the treatment of cancer

Country Status (15)

Country Link
US (13) US7282493B2 (enExample)
EP (2) EP1716119B1 (enExample)
JP (2) JP4869077B2 (enExample)
KR (1) KR101154351B1 (enExample)
CN (1) CN102643233B (enExample)
AU (1) AU2004309395C1 (enExample)
BR (1) BRPI0418147A (enExample)
CA (1) CA2547343C (enExample)
DK (1) DK1716119T3 (enExample)
ES (1) ES2409351T3 (enExample)
IL (2) IL175911A (enExample)
NO (1) NO337933B1 (enExample)
PT (1) PT1716119E (enExample)
RU (1) RU2484086C9 (enExample)
WO (1) WO2005063714A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US7282493B2 (en) 2003-12-23 2007-10-16 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
BRPI0517268A (pt) * 2004-11-02 2008-10-07 Conforma Therapeutics Corp método para tratar uma forma de leucemia linfocìtica crÈnica
US10252088B2 (en) 2004-12-02 2019-04-09 Obagi Cosmeceuticals Llc Topical compositions and methods of manufacturing them in specifically treated steel vessels
WO2006098761A2 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
US11457813B2 (en) 2005-03-29 2022-10-04 Martin W. Roche Method for detecting body parameters
CA2604473A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either
GB0517886D0 (en) * 2005-09-02 2005-10-12 Biotica Tech Ltd Novel compounds
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
WO2007098229A2 (en) * 2006-02-21 2007-08-30 Michigan State University Geldanamycin derivatives and method of use thereof
GB0606548D0 (en) * 2006-03-31 2006-05-10 Biotica Tech Ltd Novel compounds and methods for their production
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
KR20090075856A (ko) * 2006-11-09 2009-07-09 바이오티카 테크놀로지 리미티드 신규한 화합물 및 이의 제조방법
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
EP2121957A4 (en) * 2007-01-26 2010-11-10 Kosan Biosciences Inc MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS
BRPI0810835A2 (pt) * 2007-04-12 2015-06-16 Infinity Discovery Inc Formulações de hidroquinona ansamicina
WO2008154441A1 (en) * 2007-06-07 2008-12-18 Joyant Pharmaceuticals, Inc. Methods for preparing diazonamides
US8551964B2 (en) 2007-08-23 2013-10-08 The Regents Of The University Of Colorado Hsp90 inhibitors with modified toxicity
EP2348845A4 (en) * 2008-10-15 2013-01-23 Infinity Pharmaceuticals Inc ANSAMYCIN HYDROQUINONE COMPOSITIONS
US8669289B2 (en) * 2009-04-24 2014-03-11 The Jackson Laboratory Methods and compositions relating to hematologic malignancies
WO2010135426A1 (en) * 2009-05-19 2010-11-25 Infinity Pharmaceuticals, Inc. Methods of treating liposarcoma
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US20110118298A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2013074695A1 (en) 2011-11-14 2013-05-23 The Regents Of The University Of Colorado, A Body Corporate Hsp90 inhibitors with modified toxicity
CN108028172B (zh) * 2015-09-19 2022-07-29 应用材料公司 使用硅氢加成钝化的表面选择性原子层沉积
US10052304B2 (en) * 2015-10-12 2018-08-21 University Of Iowa Research Foundation Compositions and methods for cancer therapy
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2106111A (en) * 1981-09-17 1983-04-07 Takeda Chemical Industries Ltd Macbecin derivatives and their production
WO1993014215A1 (en) * 1992-01-06 1993-07-22 Pfizer Inc. Process and uses for 4,5-dihydrogeldanamycin and its hydroquinone
WO1995001342A1 (en) * 1993-06-29 1995-01-12 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
WO2003013430A2 (en) * 2001-08-06 2003-02-20 Kosan Biosciences, Inc. Benzoquinone ansamycins

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US120578A (en) 1871-11-07 Improvement in letter-boxes
US123640A (en) 1872-02-13 Improvement in tab-plates of buckles
US745718A (en) * 1903-04-25 1903-12-01 Owen Thomas Dougherty Weight-indicating sliding and spring support for vehicle-bodies.
GB210611A (en) * 1923-01-16 1924-02-07 Clarence Hancock Improved means of heating garden propagating frames, foster mothers and the like
US3595955A (en) 1969-03-26 1971-07-27 Upjohn Co Geldanamycin and process for producing same
JPS5470299A (en) * 1977-11-14 1979-06-05 Takeda Chem Ind Ltd Production of maytansine derivative
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS5874651A (ja) * 1981-09-17 1983-05-06 Takeda Chem Ind Ltd マクベシン誘導体およびその製造法
US4762857A (en) * 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
ZA878877B (en) 1986-11-29 1988-05-24 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Treatment of diseases caused by viruses
US5397584A (en) * 1992-12-09 1995-03-14 Mccormick & Company, Inc. Process for preparing stabilized, partially-dehydrated aromatic plant products
US5387584A (en) 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
WO1996040265A1 (en) 1995-06-07 1996-12-19 The Regents Of The University Of California Stabilization of polynucleotide complexes
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
WO1999051223A1 (en) 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
EP1098666B1 (en) 1998-07-17 2013-01-16 The United States of America, represented by the Secretary, Department of Health and Human Services Water-soluble drugs and methods for their production
US6174875B1 (en) 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
US6887853B2 (en) 2000-06-29 2005-05-03 The Trustees Of Boston University Use of geldanamycin and related compounds for treatment of fibrogenic disorders
US6946456B2 (en) 2000-07-28 2005-09-20 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
PT1373215E (pt) * 2001-03-30 2006-12-29 Uni S Of A R By The S D Of H H Derivado de geldanamicina e metodo de tratamento de cancro utilizando o mesmo
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
JP2005515164A (ja) * 2001-08-06 2005-05-26 コーサン バイオサイエンシーズ， インコーポレイテッド ベンゾキノンアンサマイシン
JP2005504086A (ja) 2001-09-24 2005-02-10 コンフォーマ セラピューティクス コーポレーション １７−アリルアミノゲルダナマイシン（１７−ａａｇ）および他のアンサマイシン類を製造する方法
EP1519735A4 (en) * 2001-12-12 2006-01-11 Conforma Therapeutic Corp ASSAYS AND DEVICES FOR DETERMINING AND MODULATING HSP90 BINDING ACTIVITY
US7465718B2 (en) * 2002-02-08 2008-12-16 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
TW200303363A (en) 2002-02-25 2003-09-01 Upjohn Co Process to prepare and isolate geldanamycin
CN101912601B (zh) 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
CA2518836A1 (en) 2003-03-13 2004-09-30 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20060019941A1 (en) 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
US7282493B2 (en) 2003-12-23 2007-10-16 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
JP2007530596A (ja) 2004-03-26 2007-11-01 バン アンデル リサーチ インスティチュート ゲルダナマイシンおよび誘導体はガン浸潤を阻害し、新規な標的を同定する
WO2006098761A2 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
EP1906950A4 (en) 2005-06-21 2008-09-24 Infinity Discovery Inc ANSAMYCIN FORMULATIONS AND METHODS OF USE
KR20080027896A (ko) 2005-06-29 2008-03-28 교와 핫꼬 고교 가부시끼가이샤 벤제노이드 안사마이신 유도체
CN101360492A (zh) 2005-12-01 2009-02-04 康福玛医药公司 含安莎霉素的组合物
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
BRPI0810835A2 (pt) 2007-04-12 2015-06-16 Infinity Discovery Inc Formulações de hidroquinona ansamicina
US9907242B2 (en) 2016-02-18 2018-03-06 Seminis Vegetable Seeds, Inc. Pepper hybrid SV5873HE

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2106111A (en) * 1981-09-17 1983-04-07 Takeda Chemical Industries Ltd Macbecin derivatives and their production
WO1993014215A1 (en) * 1992-01-06 1993-07-22 Pfizer Inc. Process and uses for 4,5-dihydrogeldanamycin and its hydroquinone
WO1995001342A1 (en) * 1993-06-29 1995-01-12 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
WO2003013430A2 (en) * 2001-08-06 2003-02-20 Kosan Biosciences, Inc. Benzoquinone ansamycins

Also Published As

Publication number Publication date
US8703755B2 (en) 2014-04-22
CN102643233B (zh) 2015-11-25
IL175911A0 (en) 2006-10-05
IL206984A0 (en) 2011-07-31
US7375217B2 (en) 2008-05-20
US7579337B2 (en) 2009-08-25
US20050288269A1 (en) 2005-12-29
US8003634B2 (en) 2011-08-23
IL206984A (en) 2015-02-26
US7691840B2 (en) 2010-04-06
US7282493B2 (en) 2007-10-16
NO337933B1 (no) 2016-07-11
US20050227955A1 (en) 2005-10-13
NO20062707L (no) 2006-09-11
HK1097410A1 (en) 2007-06-22
RU2484086C2 (ru) 2013-06-10
JP5313308B2 (ja) 2013-10-09
AU2004309395A1 (en) 2005-07-14
JP2011225614A (ja) 2011-11-10
ES2409351T3 (es) 2013-06-26
DK1716119T3 (da) 2013-06-10
US20090088414A1 (en) 2009-04-02
RU2006126797A (ru) 2008-01-27
US20090069280A1 (en) 2009-03-12
EP1716119B1 (en) 2013-03-06
US20090208590A1 (en) 2009-08-20
PT1716119E (pt) 2013-06-04
US20090062250A1 (en) 2009-03-05
US20090253653A1 (en) 2009-10-08
US20060014731A1 (en) 2006-01-19
CN102643233A (zh) 2012-08-22
US20090209549A1 (en) 2009-08-20
US7608613B2 (en) 2009-10-27
EP2492261B1 (en) 2015-02-18
US7361647B2 (en) 2008-04-22
IL175911A (en) 2012-01-31
US7767662B2 (en) 2010-08-03
US20130203724A1 (en) 2013-08-08
BRPI0418147A (pt) 2007-04-17
WO2005063714A1 (en) 2005-07-14
EP2492261A1 (en) 2012-08-29
CA2547343A1 (en) 2005-07-14
KR101154351B1 (ko) 2012-06-15
KR20060132660A (ko) 2006-12-21
CA2547343C (en) 2013-05-14
JP4869077B2 (ja) 2012-02-01
US7566706B2 (en) 2009-07-28
US8252779B2 (en) 2012-08-28
US20060019939A1 (en) 2006-01-26
JP2007528875A (ja) 2007-10-18
AU2004309395B2 (en) 2011-10-06
US20120058982A1 (en) 2012-03-08
US20110086110A1 (en) 2011-04-14
EP1716119A1 (en) 2006-11-02
US7833997B2 (en) 2010-11-16
RU2484086C9 (ru) 2013-08-20
US7767663B2 (en) 2010-08-03

Similar Documents

Publication Publication Date Title
AU2004309395B2 (en) Analogs of benzoquinone-containing ansamycins for the treatment of cancer
US20060019941A1 (en) Analogs of benzoquinone-containing ansamycins and methods of use thereof
JP2011225614A5 (enExample)
MXPA06007120A (en) Analogs of benzoquinone-containing ansamycins for the treatment of cancer
HK1097410B (en) Analogs of benzoquinone-containing ansamycins for the treatment of cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 MAR 2012.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 MAR 2012

MK14 Patent ceased section 143(a) (annual fees not paid) or expired